S1P promotes IL-6 expression in osteoblasts through the PI3K, MEK/ERK and NF-κB signaling pathways.


Journal

International journal of medical sciences
ISSN: 1449-1907
Titre abrégé: Int J Med Sci
Pays: Australia
ID NLM: 101213954

Informations de publication

Date de publication:
2020
Historique:
received: 06 02 2020
accepted: 27 04 2020
entrez: 18 6 2020
pubmed: 18 6 2020
medline: 9 3 2021
Statut: epublish

Résumé

Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disease, in which the immune system attacks joint tissue. Interleukin (IL)-6 is a key proinflammatory cytokine in RA progression. Sphingosine-1-phosphate (S1P), a platelet-derived lysophospholipid mediator, reportedly regulates osteoimmunology. Here, we examined the effects of S1P on IL-6 expression in osteoblasts. Our results and records from the Gene Expression Omnibus (GEO) database demonstrate higher levels of IL-6 in patients with RA compared with those with osteoarthritis. Stimulation of osteoblasts with S1P increased mRNA and protein expression of IL-6. PI3K, MEK, ERK and NF-κB inhibitors and their small interfering RNAs (siRNAs) reduced S1P-promoted IL-6 expression. S1P also facilitated PI3K, MEK/ERK and NF-κB signaling cascades. Our results indicate that S1P promotes the expression of IL-6 in osteoblasts via the PI3K, MEK/ERK and NF-κB signaling pathways.

Identifiants

pubmed: 32547316
doi: 10.7150/ijms.44612
pii: ijmsv17p1207
pmc: PMC7294913
doi:

Substances chimiques

Interleukin-6 0
Lysophospholipids 0
NF-kappa B 0
sphingosine 1-phosphate 26993-30-6
Sphingosine NGZ37HRE42

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1207-1214

Informations de copyright

© The author(s).

Déclaration de conflit d'intérêts

Competing Interests: The authors have declared that no competing interest exists.

Références

Int J Mol Sci. 2019 Apr 02;20(7):
pubmed: 30987068
Dev Comp Immunol. 2017 Aug;73:124-130
pubmed: 28344171
Nat Rev Rheumatol. 2015 Oct;11(10):606-15
pubmed: 26195338
J Food Biochem. 2019 Jul;43(7):e12902
pubmed: 31353708
Mol Oncol. 2017 Oct;11(10):1380-1398
pubmed: 28672103
Arthritis Rheum. 2012 Oct;64(10):3344-54
pubmed: 22674286
Int J Mol Sci. 2018 Jul 10;19(7):
pubmed: 29996499
Int J Mol Sci. 2019 Dec 17;20(24):
pubmed: 31861214
Clin Calcium. 2015 Dec;25(12):1851-7
pubmed: 26608861
Environ Toxicol. 2018 Oct;33(10):1061-1068
pubmed: 30098273
Immunity. 2019 Apr 16;50(4):1007-1023
pubmed: 30995492
Biochem Pharmacol. 2018 Aug;154:234-242
pubmed: 29730230
Front Immunol. 2019 Jun 25;10:1409
pubmed: 31293578
J Immunol. 2009 Aug 15;183(4):2785-92
pubmed: 19635908
Int J Mol Sci. 2018 Jan 08;19(1):
pubmed: 29316707
Ann Rheum Dis. 2016 Feb;75(2):459-65
pubmed: 25498120
PLoS One. 2019 Jun 7;14(6):e0218090
pubmed: 31173610
J Am Soc Nephrol. 1999 Jul;10(7):1466-77
pubmed: 10405202
Cancers (Basel). 2017 May 17;9(5):
pubmed: 28513565
N Engl J Med. 2001 Mar 22;344(12):907-16
pubmed: 11259725
Nat Immunol. 2015 May;16(5):448-57
pubmed: 25898198
Mol Cell Biol. 2005 May;25(10):4237-49
pubmed: 15870293
Circ Res. 2002 Feb 22;90(3):325-32
pubmed: 11861422
J Biol Chem. 2011 Apr 1;286(13):11056-66
pubmed: 21278254
Arthritis Res Ther. 2014;16(5):429
pubmed: 25606593
PLoS One. 2013 Sep 27;8(9):e75551
pubmed: 24086566
Biochem Pharmacol. 2019 Aug;166:23-32
pubmed: 31075265
Cell Commun Signal. 2018 Sep 5;16(1):55
pubmed: 30185178
Int J Mol Sci. 2015 Dec 25;17(1):
pubmed: 26712749
Clin Exp Rheumatol. 2008 Jul-Aug;26(4):632-7
pubmed: 18799095
Environ Toxicol. 2019 Feb;34(2):203-209
pubmed: 30421542
Biochem Pharmacol. 2018 Sep;155:537-546
pubmed: 30031810
J Pineal Res. 2019 Apr;66(3):e12560
pubmed: 30648758
J Cell Sci. 2012 May 1;125(Pt 9):2267-75
pubmed: 22344262
J Bone Miner Res. 2017 Jan;32(1):34-45
pubmed: 27465842

Auteurs

Sung-Lin Hu (SL)

School of Medicine, China Medical University, Taichung, Taiwan.
Department of Family Medicine, China Medical University Hsinchu Hospital, Hsinchu, Taiwan.

Chien-Chung Huang (CC)

School of Medicine, China Medical University, Taichung, Taiwan.
Division of Immunology and Rheumatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.

Tzu-Ting Tzeng (TT)

Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.

Shan-Chi Liu (SC)

Department of Medical Education and Research, China Medical University Beigang Hospital, Yunlin, Taiwan.

Chun-Hao Tsai (CH)

Department of Sports Medicine, College of Health Care, China Medical University, Taichung, Taiwan.
Department of Orthopedic Surgery, China Medical University Hospital, Taichung, Taiwan.

Yi-Chin Fong (YC)

Department of Sports Medicine, College of Health Care, China Medical University, Taichung, Taiwan.
Department of Orthopedic Surgery, China Medical University Beigang Hospital, Yunlin, Taiwan.

Chih-Hsin Tang (CH)

School of Medicine, China Medical University, Taichung, Taiwan.
Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Chinese Medicine Research Center, China Medical University, Taichung, Taiwan.
Department of Biotechnology, College of Health Science, Asia University, Taichung, Taiwan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH